HomeAI · summaries
Storia in 3 fonti
Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns
Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue involving the active pharmaceutical ingredient (API). The company said patient safety and regulatory filings remain unaffected, while an investigation is underway to identify the root cause and restore supplies.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies
Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient…
- ·
thehindubusinessline.com
Dr Reddy's delays semaglutide supply due to active ingredient issue
Dr. Reddy's delays semaglutide supply due to ingredient issues, impacting shares but posing no safety risks.
